Request Demo
Last update 20 Mar 2025
Isophane Protamine Recombinant Human Insulin(Hefei Tianmai Biotechnology Development Co., Ltd.)
Last update 20 Mar 2025
Overview
Basic Info
Drug Type Hormone |
Synonyms- |
Target |
Action agonists |
Mechanism INSR agonists(Insulin receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date China (05 Sep 2019), |
Regulation- |
Login to view timeline
Related
3
Clinical Trials associated with Isophane Protamine Recombinant Human Insulin(Hefei Tianmai Biotechnology Development Co., Ltd.)CTR20150616
评价精蛋白重组人胰岛素注射液（预混50/50）在中国2型或1型糖尿病患者中的有效性和安全性
[Translation] To evaluate the efficacy and safety of protamine recombinant human insulin injection (premixed 50/50) in Chinese patients with type 2 or type 1 diabetes
CTR20150485
评价精蛋白重组人胰岛素注射液（预混30/70）在中国2型或1型糖尿病患者中的有效性和安全性
[Translation] To evaluate the efficacy and safety of protamine recombinant human insulin injection (premixed 30/70) in Chinese patients with type 2 or type 1 diabetes
CTR20140767
旨在观察精蛋白重组人胰岛素注射液在治疗中国糖尿病患者（2 型或1 型）时的有效性和安全性
[Translation] To observe the efficacy and safety of protamine recombinant human insulin injection in the treatment of Chinese patients with diabetes (type 2 or type 1)
100 Clinical Results associated with Isophane Protamine Recombinant Human Insulin(Hefei Tianmai Biotechnology Development Co., Ltd.)
Login to view more data
100 Translational Medicine associated with Isophane Protamine Recombinant Human Insulin(Hefei Tianmai Biotechnology Development Co., Ltd.)
Login to view more data
100 Patents (Medical) associated with Isophane Protamine Recombinant Human Insulin(Hefei Tianmai Biotechnology Development Co., Ltd.)
Login to view more data
100 Deals associated with Isophane Protamine Recombinant Human Insulin(Hefei Tianmai Biotechnology Development Co., Ltd.)
Login to view more data
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Diabetes Mellitus | China | 05 Sep 2019 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Diabetes Mellitus, Type 1 | Phase 1 | China | 11 Dec 2014 | |
| Diabetes Mellitus, Type 2 | Phase 1 | China | 11 Dec 2014 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free